English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/66201
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor

AuthorsBossini-Castillo, L.; Simeón, Carmen P.; Beretta, L.; Broen, Jasper C.; Vonk, Madelon C.; Callejas-Rubio, J. L.; Carreira, P.; Rodríguez-Rodríguez, Luis; García-Portales, Rosa; González-Gay, M. A.; Castellví, I.; Camps, M. T.; Tolosa, Carlos; Vicente-Rabaneda, Esther; Egurbide, M. V.; Spanish Scleroderma Group; Schuerwegh, A. J.; Hesselstrand, R.; Lunardi, C.; Laar, Jacob M. van; Shiels, Paul G.; Herrick, A.; Worthington, J.; Denton, C.; Radstake, T. R.; Fonseca, C.; Martín, J.
Issue Date27-Dec-2012
PublisherBioMed Central
CitationArthritis Research & Therapy 14(6) : R273 (2012)
AbstractAbstract Introduction Potassium voltage-gated channel shaker-related subfamily member 5 (KCNA5) is implicated in vascular tone regulation, and its inhibition during hypoxia produces pulmonary vasoconstriction. Recently, a protective association of the KCNA5 locus with systemic sclerosis (SSc) patients with pulmonary arterial hypertension (PAH) was reported. Hence, the aim of this study was to replicate these findings in an independent multicenter Caucasian SSc cohort. Methods The 2,343 SSc cases (179 PAH positive, confirmed by right-heart catheterization) and 2,690 matched healthy controls from five European countries were included in this study. Rs10744676 single-nucleotide polymorphism (SNP) was genotyped by using a TaqMan SNP genotyping assay. Results Individual population analyses of the selected KCNA5 genetic variant did not show significant association with SSc or any of the defined subsets (for example, limited cutaneous SSc, diffuse cutaneous SSc, anti-centromere autoantibody positive and anti-topoisomerase autoantibody positive). Furthermore, pooled analyses revealed no significant evidence of association with the disease or any of the subsets, not even the PAH-positive group. The comparison of PAH-positive patients with PAH-negative patients showed no significant differences among patients. Conclusions Our data do not support an important role of KCNA5 as an SSc-susceptibility factor or as a PAH-development genetic marker for SSc patients.
URIhttp://hdl.handle.net/10261/66201
Identifiershttp://dx.doi.org/10.1186/ar4124
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
ar4124.xml61,21 kBXMLView/Open
AR4124-S1.DOC71 kBMicrosoft WordView/Open
ar4124.pdf209,4 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.